ClinicalTrials.gg
CompletedNCT04106726Updated Oct 14, 2020

Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea

A Phase 3 interventional study of Soolantra® Ivermectin cream 1% and Ivermectin cream 1% in Facial Rosacea, sponsored by Zydus Worldwide DMCC. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by Zydus Worldwide DMCC (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.

Enrollment
5th of 11
525 · median 486
Started
2019
the only one that year
Phase 3
6 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
Zydus Worldwide DMCC

Among the 11 studies testing ivermectin in Rosacea, this one is the 5th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 3, and was the 8th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ivermectin in Rosacea as a file.
02

Study summary

To evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Zydus Worldwide DMCC) and Soolantra® (ivermectin) cream, 1% (Galderma Laboratories, L.P.) in the treatment of moderate to severe facial papulopustular rosacea.

To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate to severe facial rosacea.

03

Conditions studied

  • Facial Rosacea

Browse trials for

Keywords

  • Ivermectin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or non-pregnant female aged ≥ 18 years with a clinical diagnosis of facial papulopustular rosacea.
  2. Subjects must have provided IRB approved written .
  3. Subjects must have at least 15 and not more than 50 inflammatory facial lesions (i.e., papules/pustules) at screening and baseline visits. For the purposes of study treatment and evaluation, these lesions should be limited to the facial treatment area including those present on the nose. Lesions involving the eyes, and scalp will be excluded from the count.
  4. Subjects must have no more than 2 nodulocystic lesions on the face at Screening and Baseline visits.
  5. Subjects must have a definite clinical diagnosis of facial papulopustular rosacea severity grade 3 or 4 as per the Investigator Global Assessment (IGA) (per Table 1 below) at screening and baseline visits.
  6. Subjects must have persistent erythema on the face with moderate (2) score or higher (per table 2 below) at screening and baseline visits.
  7. Subjects must have a mild (1) to moderate (2) score for telangiectasia on the face. (per table 3 below) at screening and baseline visits.
    1. Subjects must be willing to minimize external factors that might trigger rosacea flare-ups (e.g., spicy foods, thermally hot foods and drinks, hot environments, prolonged sun exposure, strong winds and alcoholic beverages)
  8. Subjects must be willing to refrain from using all other topical medications for rosacea during the 12-week treatment period, other than the product.
  9. Female Subjects of (excluding women who are or premenarchal, surgically sterilized (by hysterectomy) or for at least 1 year prior to screening), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of during the study from the day of the first dose administration to 30 days after the last administration of study drug. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (stabilized for at least 3 months prior to screening), NuvaRing® (vaginal contraceptive), Implanon™ (contraceptive implant), double-barrier methods (e.g. condom and spermicide), IUD, or abstinence with a 2nd acceptable method of birth control should the Subject become sexually active. Subjects on hormonal contraception must be stabilized on the same type for at least three months prior to screening and must not change the method during the study. A sterile sexual partner is NOT considered an adequate form of birth control.
  10. All male Subjects must agree to use accepted methods of birth control with their partners, from the day of the first dose administration to 30 days after the last administration of study drug. Abstinence is an acceptable method of birth control. Female partners should use an acceptable method of birth control as described in the above Item Number 10.
  11. Subjects who use make-up must have used the same brands/types of make-up for a minimum period of 14 days prior to screening and must agree to not change make-up brand/type or frequency of use throughout the study.
  12. Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits.
  13. Subjects must be in good health and free from any disease, including but not limited to, conditions that may interfere with the evaluation of facial rosacea. Such conditions include but are not limited to the following: disease; acne vulgaris on the face; seborrheic dermatitis on the face; perioral dermatitis; -induced acne; carcinoid syndrome; mastocytosis; acneiform eruptions caused by make-up, medication, facial psoriasis and facial eczema.

Exclusion criteria

Exclusion Criteria:

  1. Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
  2. Subjects with a history of or allergy to ivermectin, propylene glycol and/or any of the study medication ingredients and its .
  3. Subjects with the presence of other forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other dermatoses that may be confounded with papulopustular rosacea, such as peri-oral dermatitis, facial keratosis pilaris, seborrheic dermatitis and acne.
  4. Subjects with excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of facial rosacea.
  5. Subjects with moderate or severe rhinophyma, dense telangiectases (score 3, severe), or plaque-like facial edema.
  6. Subjects with a severe irritation (score 3 = severe (marked/intense)) for dryness, pruritus, or stinging/burning.
  7. Subjects with ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.
  8. Subjects who currently have or have recently had bacterial folliculitis on the face.
  9. Subjects who have unstable medical disorders that are or have lifethreatening diseases. Subjects who have clinically significant abnormal laboratory values according to the investigator at screening.
  10. Subjects who had within 14 days prior to screening:

    1. wax depilation of the face
    2. cosmetic procedures (e.g., facials) which may affect assessment of facial rosacea
    3. exposure to excessive UV radiation or the subject is planning exposure during the study (e.g. occupational exposure to the sun, planned holidays in the sun during the study, phototherapy, tanning salon),
    4. used a sauna.
  11. Subjects who have used any of the following procedures on the face within 1 month prior to screening:

    1. cryodestruction or chemodestruction,
    2. dermabrasion,
    3. photodynamic therapy,
    4. acne surgery,
    5. intralesional , or
    6. X-ray therapy.
  12. Subjects who have used any of the following topical treatments on the face within 1 month prior to screening:

    1. retinoids
    2. benzoyl peroxide
    3. immunomodulators
    4. antibiotics (e.g., metronidazole and macrolides)
    5. corticosteroids
    6. other topical rosacea treatment (e.g., azelaic acid, metronidazole) or topical erythema treatment (e.g. brimonidine)
  13. Subjects who have used any of the following systemic treatments within 1 month prior to screening:

    1. corticosteroids,
    2. systemic antibiotics known to have an impact on the severity of facial rosacea (e.g., containing tetracycline and its derivatives, erythromycin and its derivatives, sulfamethoxazole, or trimethoprim),
    3. other systemic treatments that affect erythema: alpha-blockers (e.g., mirtazapine), beta-blockers (e.g., propranolol), alpha 2 agonist (e.g., clonidine), or
    4. other systemic treatment for rosacea.
  14. Subjects who have used any of the following topical treatments within 6 weeks prior to screening:

    1. corticosteroids,
    2. antibiotics for rosacea,
    3. medications for rosacea (e.g., azelaic acid, metronidazole),
    4. over-the-counter preparations for rosacea, or
    5. anti-inflammatory agents. Note: Non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin use on an as needed basis and if not used consecutively for > 14 days prior to screening and/or during the study is acceptable. Note: Low dose (81 mg) aspirin taken daily is acceptable.
  15. Subjects who have used or changed their use of estrogens or oral within the 3 months prior to screening.
  16. Subjects who have received radiation therapy and/or anti-neoplastic agents within 3 months prior to screening.
  17. Subjects who have used within 6 months prior to screening antiandrogens such as Spironolactone, oral retinoids (e.g. Accutane®), or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  18. Subjects who have had laser therapy (for telangiectasia or other conditions), electrodessication and phototherapy (e.g., ClearLight®) to the facial area within 6 months prior to study entry (Visit 1 Screening Visit).
  19. Subjects who engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes, such as wind or cold.
  20. Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates).
  21. Subjects who have participated in an drug study (i.e., Subjects have been treated with an investigational drug) within 30 days prior to screening will be excluded from study participation. Subjects who are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion.
  22. Subjects who have been previously enrolled in this study.
  23. Subjects who live in the same household with subjects currently enrolled in this trial.
  24. Subjects who have a history of being unresponsive to topical ivermectin therapy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
525 participants (actual)

Study arms

  • Experimental
    Test: Ivermectin cream 1%

    Manufactured by Zydus Worldwide DMCC; Apply cream to the affected areas of the face once daily for 12 weeks.

    Drug: Ivermectin cream 1%

  • Active comparator
    Reference: Soolantra® cream, 1%

    Manufactured by Galderma Laboratories, L.P.; Apply cream to the affected areas of the face once daily for 12 weeks.

    Drug: Soolantra® Ivermectin cream 1%

  • Placebo comparator
    Placebo: Placebo for Ivermectin cream 1%

    Manufactured by Zydus Worldwide DMCC; Apply to the affected areas of the face once daily for 12 weeks.

    Drug: Placebo for Ivermectin cream 1%

Interventions

  • DrugSoolantra® Ivermectin cream 1%

    Apply topically to the face once daily for 84 consecutive days.

  • Apply topically to the face once daily for 84 consecutive days.

  • DrugPlacebo for Ivermectin cream 1%

    Apply topically to the face once daily for 84 consecutive days.

06

What researchers measure

Primary outcomes

  1. Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.

    Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.

    Time frame: 12 weeks

Secondary outcomes

  1. Exploratory Endpoint: The proportion of subjects with a clinical response (IGA) of "success" at week 12.

    The proportion of subjects with a clinical response (IGA) of "success" at week 12.

    Time frame: 12 weeks

07

Study locations

11 sites
  • Zydus Worldwide DMCC
    Brandon, Florida 33511, United States
  • Zydus Worldwide DMCC
    Fort Lauderdale, Florida 33308, United States
  • Zydus Worldwide DMCC
    Miami, Florida 33175, United States
  • Zydus Worldwide DMCC
    Miramar, Florida 33027, United States
  • Zydus Worldwide DMCC
    Tampa, Florida 33609, United States
  • Zydus Worldwide DMCC
    Saginaw, Michigan 48604, United States
  • Zydus Worldwide DMCC
    High Point, North Carolina 27262, United States
  • Zydus Worldwide DMCC
    Sugarloaf, Pennsylvania 18249, United States
  • Zydus Worldwide DMCC
    Upper Saint Clair, Pennsylvania 15241, United States
  • Zydus Worldwide DMCC
    El Paso, Texas 79902, United States
  • Zydus Worldwide DMCC
    El Paso, Texas 79925, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Aug 2020, 9 months.

Of 17 phase 3 interventional studies under Rosacea, half reached primary completion within 11 months of starting (the median); a quarter within 9 and three quarters within 15. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Sep 27, 2019
StartActual
Oct 17, 2019
Primary completionActual
Aug 4, 2020
CompletionActual
Aug 4, 2020
Last update
Oct 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04106726
Collaborators
Catawba Research, LLC
Responsible party
Sponsor
First posted
Sep 27, 2019
Start date
Oct 17, 2019
Primary completion
Aug 4, 2020
Completion
Aug 4, 2020
Last update
Oct 14, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion